SCHEDULE: Ayrton Capital LLC Discloses 9.99% Stake in Glucotrack

A Schedule 13G filing reveals Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri collectively hold a 9.99% stake in Glucotrack, Inc., acquired through convertible notes.

Summary

• Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri have collectively reported beneficial ownership of 94,271 shares of Glucotrack, Inc. common stock.
• This ownership stake represents 9.99% of the class of securities.
• The reported shares are issuable upon the conversion of certain convertible notes held by the reporting persons.
• The beneficial ownership is subject to a 9.99% beneficial ownership blocker.
• The filing is made under Schedule 13G, indicating passive investment intent.
• The outstanding shares of common stock as of September 23, 2026, were 848,629.
• The reporting persons' holdings are as of September 30, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant ownership stake by an investment manager and related entities, which could signal confidence, but without explicit forward-looking statements about company performance.

Positives

• Significant stake acquired by investment entities, potentially indicating confidence in the company's future.
• The reporting persons hold sole voting and dispositive power over the 94,271 shares.
• The filing indicates a passive investment strategy, which is typical for institutional investors seeking long-term value.

Negatives

• The ownership is derived from convertible notes, not direct share purchases, which carries conversion risks.
• The 9.99% ownership blocker limits further accumulation without triggering a more stringent filing requirement.

Risks

• The value of the investment is tied to the conversion of notes, which is contingent on the company's performance and stock price.
• Potential for future dilution if the company issues more stock.
• The 9.99% ownership limit may restrict the reporting persons' ability to influence company control, even if they desired to do so.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding Glucotrack, Inc.'s future performance. The disclosure pertains to ownership of existing securities through convertible notes.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by passive investors who acquire more than 5% of a company's stock. The involvement of an investment manager like Ayrton Capital LLC and a master fund suggests institutional interest in Glucotrack, Inc., which is common in sectors with high growth potential or significant technological innovation.

Stakeholder Impact

• Shareholders: The acquisition of a significant stake by institutional investors can be viewed positively, potentially signaling future growth or stability, but the passive nature of the filing means no immediate influence on control is implied.
• Creditors: The filing does not directly impact creditors, but the company's overall financial health, which influences the value of convertible notes, remains a key factor.
• Management: The reporting persons have certified that the securities were not acquired to influence control, suggesting no immediate intent to disrupt current management.

Next Steps

• Monitor Glucotrack, Inc.'s financial performance and strategic developments to assess the value of the convertible notes.
• Observe any future filings by Ayrton Capital LLC or related entities for changes in beneficial ownership.
• Evaluate the company's progress in its core business activities, which would impact the conversion value of the notes.

Key Dates

Recommendation

Based on this Schedule 13G filing, the recommendation is 'hold'. The filing indicates a significant passive investment by institutional entities, which is generally a neutral to positive signal. However, it does not provide new operational or financial performance data for Glucotrack, Inc. itself, nor does it suggest any immediate catalyst for a price change. The investment is tied to convertible notes, adding a layer of complexity and risk that warrants caution rather than a strong buy or sell.

Keywords

Glucotrack, Ayrton Capital LLC, Alto Opportunity Master Fund, Waqas Khatri, Convertible Notes, Beneficial Ownership, Schedule 13G, Investment Manager